Orchestra BioMed Holdings, Inc. (OBIO)

Market Cap	200.71M
Revenue (ttm)	2.65M
Net Income (ttm)	-57.69M
Shares Out	38.01M
EPS (ttm)	-1.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,140
Open	5.14
Previous Close	5.17
Day's Range	5.06 - 5.28
52-Week Range	4.22 - 11.69
Beta	0.41
Analysts	Strong Buy
Price Target	15.75 (+198.3%)
Earnings Date	Nov 12, 2024

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: OBIO
• Website: https://orchestrabiomed.com

Financial Performance

In 2023, Orchestra BioMed Holdings's revenue was $2.76 million, a decrease of -21.88% compared to the previous year's $3.53 million. Losses were -$49.12 million, 46.2% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price forecast is $15.75, which is an increase of 198.30% from the latest price.

Price Target

$15.75

(198.30% upside)

Analyst Consensus: Strong Buy